4.6 Review

The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact

期刊

PLOS ONE
卷 12, 期 5, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0176797

关键词

-

资金

  1. scientific advisory boards
  2. Merck

向作者/读者索取更多资源

Background Clostridium difficile infection (CDI) is the most common healthcare associated infection and is highly prevalent in Europe and North America. Limited data is available on the prevalence of CDI in Asia. However, secular increases in prevalence of risk factors for CDI suggest that it may be emerging as a major cause of morbidity, highlighting the urgent need for a systematic study of the prevalence of CDI in Asia. Methods We systematically searched PubMed/Medline and Embase for publications from Asia between 2000-16 examining prevalence of CDI. A random-effects meta-analysis was performed to calculate the pooled prevalence of CDI in Asia and to identify subgroups and regions at high risk. Results Our meta-analysis included 51 studies from throughout Asia including 37,663 patients at risk among whom confirmed CDI was found in 4,343 patients. The pooled proportion of confirmed CDI among all patients with diarrhea was 14.8% with a higher prevalence in East Asia (19.5%), compared with South Asia (10.5%) or the Middle East (11.1%). There were an estimated 5.3 episodes of CDI per 10,000 patient days, similar to rates reported from Europe and North America. Infections due to hypervirulent strains were rare. CDI-related mortality was 8.9%. Conclusions In a meta-analysis of 51 studies, we observed similar rates of CDI in Asia in comparison to Europe and North America. Increased awareness and improved surveillance of Clostridium difficile is essential to reduce incidence and morbidity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty

Bharati D. Kochar, Winston Cai, Ashwin N. Ananthakrishnan

Summary: This study found that treatment response is a key factor in determining post-treatment frailty in IBD patients. Pre-treatment frailty and prior IBD-related hospitalization were independently predictive of higher likelihood of post-treatment frailty. Effective treatment of inflammatory states in older patients with IBD may improve frailty.

DIGESTIVE DISEASES AND SCIENCES (2022)

Article Gastroenterology & Hepatology

Yield and Predictors of Surveillance Colonoscopies in Older Adults With Long-standing Ulcerative Colitis

Alexa N. Sasson, Gabriel Sheehan, Amy Yu, Akshita Gupta, Kelly Ling, Bharati Kochar, Ashwin N. Ananthakrishnan

Summary: Continued endoscopic surveillance may have a low yield in patients aged 75 or above with long-standing UC who do not have prior dysplasia.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases

Alexa N. Sasson, Ashwin N. Ananthakrishnan

Summary: This study suggests that patients with high titers of anti-drug antibodies to infliximab are as likely to respond to adalimumab therapy as those with low titers, indicating that high titers of antibodies are not predictive of treatment failure.

DIGESTIVE DISEASES AND SCIENCES (2022)

Article Gastroenterology & Hepatology

Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts

Kevin Casey, Emily W. Lopes, Blake Niccum, Kristin Burke, Ashwin N. Ananthakrishnan, Paul Lochhead, James M. Richter, Andrew T. Chan, Hamed Khalili

Summary: A prospective study of over 230,000 participants found no significant association between alcohol consumption and risk of CD or UC. Only moderate consumption of beer was marginally associated with reduced risk of CD, while higher consumption of liquor was associated with an increased risk of UC. Further investigation into the relationship between alcohol types and risk of CD and UC is warranted.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Article Gastroenterology & Hepatology

Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases

Bharati D. Kochar, David Cheng, Tianxi Cai, Ashwin N. Ananthakrishnan

Summary: This retrospective cohort study using a US claims database found that tofacitinib, used to treat IBD, did not increase the risk of adverse thrombotic events compared to anti-TNF therapy.

DIGESTIVE DISEASES AND SCIENCES (2022)

Article Gastroenterology & Hepatology

Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis

Saranya Sasidharan, Alexa N. Sasson, Kevin M. Shannon, Ashwin N. Ananthakrishnan

Summary: This study assessed the predictive efficacy of fecal calprotectin in identifying the need for medical or surgical therapy in patients with acute severe colitis. The results demonstrated that patients with higher fecal calprotectin levels were more likely to require in-hospital medical rescue therapy or surgery. This predictive marker has the potential to facilitate earlier therapeutic interventions and improve patient outcomes.

INFLAMMATORY BOWEL DISEASES (2022)

Article Gastroenterology & Hepatology

A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease

Katherine Falloon, Benjamin Cohen, Ashwin N. Ananthakrishnan, Edward L. Barnes, Abhik Bhattacharya, Jean-Frederic Colombel, Raymond K. Cross, Marcia S. Driscoll, Anthony P. Fernandez, Christina Ha, Hans Herfarth, Sara Horst, Jason Hou, M. Elaine Husni, Daniela Kroshinsky, Kristine A. Kuhn, Careen Y. Lowder, George Martin, Deep Parikh, Christopher J. Sayed, Lisa Schocket, Bernadette C. Siaton, Priyanka Vedak, Michael H. Weisman, Florian Rieder

Summary: An interdisciplinary expert panel developed consensus criteria for diagnosing and monitoring five EIMs, providing guidance for clinical practice and future trial design. Key findings include straightforward diagnostic criteria, appropriate specialists for diagnosis, and monitoring options that include patient and physician-reported outcomes. These criteria will be used to optimize the management of EIMs in a national multicenter study network.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Editorial Material Gastroenterology & Hepatology

Editorial: immunosuppression and SARS-CoV-2 vaccination-where do we stand?

Ashwin N. Ananthakrishnan

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Lifestyle factors for the prevention of inflammatory bowel disease

Emily W. Lopes, Simon S. M. Chan, Mingyang Song, Jonas F. Ludvigsson, Niclas Hakansson, Paul Lochhead, Allan Clark, Kristin E. Burke, Ashwin N. Ananthakrishnan, Amanda J. Cross, Domenico Palli, Manuela M. Bergmann, James M. Richter, Andrew T. Chan, Ola Olen, Alicja Wolk, Hamed Khalili

Summary: This study aimed to estimate the proportion of cases of Crohn's disease (CD) and ulcerative colitis (UC) that could be prevented by modifiable lifestyle factors. Using several cohorts in the US and Europe, the researchers created modifiable risk scores and healthy lifestyle scores, and found that a significant number of CD and UC cases could be prevented through lifestyle modification.
Editorial Material Gastroenterology & Hepatology

Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data

Leo Boneschansker, Ashwin N. Ananthakrishnan

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Economic Burden of Fatigue in Inflammatory Bowel Disease

Ashwin N. Ananthakrishnan, Raj Desai, Wan-Ju Lee, Jenny Griffith, Naijun Chen, Edward Loftus

Summary: This retrospective study examined the impact of fatigue on healthcare costs for newly diagnosed patients with inflammatory bowel disease (IBD). The study found that patients with fatigue had significantly higher healthcare resource utilization, hospitalization rates, and direct healthcare costs compared to those without fatigue.

CROHNS & COLITIS 360 (2023)

Article Gastroenterology & Hepatology

Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US

Katherine M. Williams, Prasanna K. Challa, Emily W. Lopes, Kristin E. Burke, Ashwin N. Ananthakrishnan, James M. Richter, Andrew T. Chan, Hamed Khalili

Summary: In two large prospective cohort studies, there was no observed association between periodontal disease and tooth loss and the risk of Crohn's disease or ulcerative colitis.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Differential Impact of Smoking on Methylome and Transcriptome in Crohn's Disease and Ulcerative Colitis

Qi Yan Ang, Damian Plichta, Sean Kim, Iris Hyun-A Kim, Sadie Gregory, Yan Xia, Helena Lau, Ramnik Xavier, Ashwin N. Ananthakrishnan

Summary: This study identified both common and differential effects of smoking on Crohn's disease (CD) and ulcerative colitis (UC). Dysfunction of Paneth cells may mediate the adverse impact of smoking on CD, while bile acid and oxidative stress pathways may be relevant for the differential effect of smoking on CD and UC.

INFLAMMATORY BOWEL DISEASES (2023)

Review Gastroenterology & Hepatology

Precision medicine in inflammatory bowel diseases

Ashwin N. Ananthakrishnan

Summary: Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are common global diseases. Limited data is available to determine the relative positioning of different therapies. This review summarizes existing literature on the use of clinical decision models to compare and evaluate the relative efficacy of various therapeutic mechanisms based on individual patient characteristics. It also highlights the significance of serologic, transcriptomic, and microbiome-based biomarkers in determining the most suitable therapy for individual patients.

INTESTINAL RESEARCH (2023)

Review Gastroenterology & Hepatology

Frailty in inflammatory bowel diseases: an emerging concept

Bharati Kochar, Ariela R. Orkaby, Ashwin N. Ananthakrishnan, Christine S. Ritchie

Summary: Inflammatory bowel diseases are chronic conditions of the gastrointestinal tract, with a rising number of cases in older adults; older adults with IBD have poorer disease outcomes compared to younger adults; frailty is a geriatric construct that may reflect biologic age and increased vulnerability to decline across multiple physiologic systems.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

暂无数据